New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on February 22, 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lilly Endowment Inc, a significant shareholder, has recently sold 14,685 shares of Eli Lilly & Co stock, generating a total revenue of $12,893,285 from the transaction.
Recent Updates on LLY stock
Recent developments for Eli Lilly & Co. include positive results from ongoing trials of their next-generation obesity drug, retatrutide, which has led to significant weight loss in participants. This promising outcome is likely contributing to investor optimism. Additionally, Eli Lilly’s collaboration with OliX Pharmaceuticals to develop OLX75016 for metabolic-associated steatohepatitis and other cardiometabolic indications signifies strategic growth initiatives. Furthermore, analysts at BofA have adjusted their price target for Eli Lilly based on strong Q4 results and favorable FY25 earnings guidance, which align with market expectations. These factors collectively indicate a positive outlook for Eli Lilly, driven by its innovative pipeline and strategic partnerships.
More about Eli Lilly & Co
YTD Price Performance: 13.29%
Average Trading Volume: 3,601,686
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $827.9B